Clinical trial
Etanercept to Treat Wegener's Granulomatosis
NCT00001901 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001901 |
|---|---|
| Title | Etanercept to Treat Wegener's Granulomatosis |
| Official title | Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatosis |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Vasculitis, Wegener's Granulomatosis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 60 |
| Start date | Feb 1, 1999 |
| Completion | Mar 1, 2005 |
| First posted | Nov 4, 1999 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: